NVision has announced a major expansion from quantum sensing into quantum computing, introducing a new photonic integrated quantum circuit platform designed to support scalable quantum systems for healthcare and drug discovery applications.
The company said its new platform, called PIQC, integrates organic molecule-based qubits directly onto photonic chips using a thin organic layer architecture compatible with semiconductor manufacturing technologies.
NVision stated that the approach builds on technology originally developed for its POLARIS quantum-enhanced MRI platform, which uses quantum sensing to improve metabolic imaging performance on standard MRI systems.
During development, the company identified a new class of organic molecule-based qubits that now form the basis of its quantum computing strategy.
According to NVision, the PIQC architecture combines integrated photonic hardware with single-photon emitting organic molecules to create a scalable quantum computing platform aimed at accelerating drug design and biological validation workflows.
The company also announced a $55m Series B funding round anchored by Abbott, with participation from Playground Global, Matterwave Ventures, Entrée Capital and the European Investment Bank.
NVision said the funding will support continued development of its quantum sensing and photonic quantum computing technologies as it expands deployments of its POLARIS systems across research and clinical centres in the US, Europe and Asia.
